Johnson & Johnson (JNJ) multiple myeloma therapies Tecvayli and Talvey boost cancer-free survival as part of a combination ...
Researchers have found that with new treatments for multiple myeloma, a serious type of blood cancer, clinicians should use ...
In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40 ...
Clinical Trials Arena on MSN
J&J’s multiple myeloma combo cuts risk of death by 62% in phase III study
The MonumenTAL-6 results add to the growing body of evidence touting Talvey and Tecvayli’s use in earlier multiple myeloma ...
Patients with multiple myeloma who received a new immunotherapy combination lived significantly longer without their cancer worsening and showed early signs of improved survival in a large ...
In a Phase I clinical trial , treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of ...
Patients with plasmacytomas that are noncontiguous with bone marrow (true extramedullary myeloma) are at high risk for disease progression or relapse. Phase 1 of the RedirecTT-1 study showed promising ...
Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) ...
Relapse commonly reflects immunoediting, with ~60%–70% of post-relapse cases linked to GPRC5D antigen changes that reduce binding/recognition by GPRC5D-directed bispecific T-cell engagers. Therapeutic ...
For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results